ZA96994B - Method of treatment for decreasing mortality resulting from congestive heart failure. - Google Patents

Method of treatment for decreasing mortality resulting from congestive heart failure.

Info

Publication number
ZA96994B
ZA96994B ZA9600994A ZA96994A ZA96994B ZA 96994 B ZA96994 B ZA 96994B ZA 9600994 A ZA9600994 A ZA 9600994A ZA 96994 A ZA96994 A ZA 96994A ZA 96994 B ZA96994 B ZA 96994B
Authority
ZA
South Africa
Prior art keywords
treatment
heart failure
congestive heart
mortality resulting
decreasing mortality
Prior art date
Application number
ZA9600994A
Other languages
English (en)
Inventor
Mary Ann Lukas-Laskey
Robert Ruffolo Jr
Neil Shusterman
Gisbert Sponer
Klaus Strein
Original Assignee
Boehringer Mannheim Pharm Corp
Smith Kline Beecham Corp Ltd P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26012210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA96994(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1995103995 external-priority patent/DE19503995C2/de
Application filed by Boehringer Mannheim Pharm Corp, Smith Kline Beecham Corp Ltd P filed Critical Boehringer Mannheim Pharm Corp
Publication of ZA96994B publication Critical patent/ZA96994B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA9600994A 1995-02-08 1996-02-08 Method of treatment for decreasing mortality resulting from congestive heart failure. ZA96994B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1995103995 DE19503995C2 (de) 1995-02-08 1995-02-08 Verwendung von Carvedilol zur Verminderung der Mortalität bei Patienten mit eingeschränkter myocardialer Funktion
US08/483,635 US5760069A (en) 1995-02-08 1995-06-07 Method of treatment for decreasing mortality resulting from congestive heart failure

Publications (1)

Publication Number Publication Date
ZA96994B true ZA96994B (en) 1997-10-27

Family

ID=26012210

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9600994A ZA96994B (en) 1995-02-08 1996-02-08 Method of treatment for decreasing mortality resulting from congestive heart failure.

Country Status (27)

Country Link
US (6) US5760069A (ru)
EP (1) EP0808162B1 (ru)
JP (1) JP3546058B2 (ru)
KR (1) KR100295940B1 (ru)
CN (1) CN1093760C (ru)
AT (1) ATE179891T1 (ru)
AU (1) AU702106C (ru)
BR (1) BR9607111A (ru)
CA (1) CA2212548C (ru)
CZ (1) CZ292002B6 (ru)
DE (1) DE69602424T2 (ru)
DK (1) DK0808162T3 (ru)
ES (1) ES2134588T3 (ru)
FI (1) FI973255A0 (ru)
GR (1) GR3030966T3 (ru)
HK (1) HK1014861A1 (ru)
HU (1) HUP9900773A3 (ru)
NO (1) NO314830B1 (ru)
NZ (1) NZ301692A (ru)
PL (1) PL321737A1 (ru)
RO (1) RO121629B1 (ru)
RU (1) RU2197242C2 (ru)
SI (1) SI0808162T1 (ru)
SK (1) SK106897A3 (ru)
UA (1) UA55382C2 (ru)
WO (1) WO1996024348A2 (ru)
ZA (1) ZA96994B (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
TR199900762T2 (xx) * 1996-10-09 1999-07-21 Boehringer Mannheim Pharmaceuticals Cor.Smithkline Beecham Stresle aktifle�tirilen protein kinazlar�n�n engellenme y�ntemi.
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
WO1999024017A1 (en) * 1997-11-12 1999-05-20 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Bechman Corporation Limited Partnership No.1 Novel oral dosage form for carvedilol
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
DE19833119A1 (de) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
US6465463B1 (en) * 1999-09-08 2002-10-15 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US7235237B2 (en) * 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
WO2001035961A1 (en) * 1999-10-29 2001-05-25 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) * 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) * 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
MXPA02012795A (es) * 2000-06-28 2004-07-30 Teva Pharma Carvedilol.
EP1385509A4 (en) * 2001-04-02 2004-06-30 Smithkline Beecham Corp TREATMENT METHOD
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
EP1465620A4 (en) * 2001-10-02 2006-01-25 Smithkline Beecham Corp NEW COMPOSITION OF CARVEDILOL
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
SE0103749D0 (sv) * 2001-11-08 2001-11-08 Sahltech Ab Treatment of congestive heart failure
PL371409A1 (en) * 2002-01-15 2005-06-13 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
EP1499310A4 (en) * 2002-04-30 2005-12-07 Sb Pharmco Inc MONOCITRATE MONOHYDRATE OF CARVEDILOL
US6951880B2 (en) * 2002-05-16 2005-10-04 Genelabs Technologies, Inc. Aryl and heteroaryl compounds as antibacterial and antifungal agents
US20050261355A1 (en) * 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
MXPA04012923A (es) * 2002-06-27 2005-03-31 Sb Pharmco Inc Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
PT1362590E (pt) * 2002-07-25 2004-05-31 Boehringer Ingelheim Pharma Utilizacao de cilobradina ou dos seus sais farmaceuticamente aceitaveis para o tratamento ou prevencao de falha cardiaca
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
US20060014829A1 (en) * 2004-07-16 2006-01-19 Nitromed, Inc. Methods for reducing hospitalizations related to heart failure
US20070043099A1 (en) * 2005-06-09 2007-02-22 Igor Lifshitz Crystalline forms of carvedilol and processes for their preparation
US20080293724A1 (en) * 2006-02-17 2008-11-27 Nitromed, Inc. Methods Using Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US8703804B2 (en) * 2006-03-26 2014-04-22 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
WO2007136626A1 (en) * 2006-05-16 2007-11-29 Nitromed, Inc. Solid dosage formulations of hydralazine compounds
US8022094B2 (en) * 2006-06-28 2011-09-20 Teva Pharmaceutical Industries Ltd. Carvedilol phosphate
WO2008105794A1 (en) * 2007-02-26 2008-09-04 Teva Pharmaceutical Industries Ltd. Process for the purification of carvedilol or its salts thereof
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
EA022948B1 (ru) 2008-05-16 2016-03-31 Кортера, Инк. Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
MX357614B (es) * 2010-04-12 2018-07-17 Supernus Pharmaceuticals Inc Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
JP2014521713A (ja) 2011-08-12 2014-08-28 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング 味をマスキングした医薬組成物
CN110381929A (zh) * 2016-06-13 2019-10-25 阿森迪亚制药有限责任公司 卡维地洛分散系统的肠胃外缓释传递
US10772869B1 (en) 2019-07-24 2020-09-15 ECI Pharmaceuticals, LLC Pharmaceutical compositions including carvedilol and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
SE460945B (sv) * 1987-01-15 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av furosemid
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure

Also Published As

Publication number Publication date
UA55382C2 (ru) 2003-04-15
US5902821A (en) 1999-05-11
KR19980702085A (ko) 1998-07-15
DE69602424D1 (de) 1999-06-17
BR9607111A (pt) 1997-11-04
EP0808162A2 (en) 1997-11-26
US5760069A (en) 1998-06-02
KR100295940B1 (ko) 2001-08-07
HUP9900773A2 (hu) 1999-07-28
DE69602424T2 (de) 1999-10-07
CA2212548C (en) 1999-08-24
JP3546058B2 (ja) 2004-07-21
US20030105138A1 (en) 2003-06-05
EP0808162B1 (en) 1999-05-12
PL321737A1 (en) 1997-12-22
CN1185106A (zh) 1998-06-17
CZ292002B6 (cs) 2003-07-16
HK1014861A1 (en) 1999-10-08
USRE40707E1 (en) 2009-05-05
GR3030966T3 (en) 1999-11-30
DK0808162T3 (da) 1999-11-15
RO121629B1 (ro) 2008-01-30
SI0808162T1 (en) 1999-10-31
USRE40000E1 (en) 2008-01-08
HUP9900773A3 (en) 2000-04-28
NO314830B1 (no) 2003-06-02
MX9706042A (es) 1998-06-30
WO1996024348A3 (en) 1996-10-03
NZ301692A (en) 2000-09-29
WO1996024348A2 (en) 1996-08-15
AU702106C (en) 2005-02-17
AU702106B2 (en) 1999-02-11
FI973255A (fi) 1997-08-07
US20010044455A1 (en) 2001-11-22
ES2134588T3 (es) 1999-10-01
NO973667D0 (no) 1997-08-08
FI973255A0 (fi) 1997-08-07
CN1093760C (zh) 2002-11-06
CZ246397A3 (cs) 1998-11-11
NO973667L (no) 1997-08-08
CA2212548A1 (en) 1996-08-15
AU4718196A (en) 1996-08-27
RU2197242C2 (ru) 2003-01-27
ATE179891T1 (de) 1999-05-15
JPH10513463A (ja) 1998-12-22
SK106897A3 (en) 1999-03-12

Similar Documents

Publication Publication Date Title
ZA96994B (en) Method of treatment for decreasing mortality resulting from congestive heart failure.
UA74346C2 (ru) Производные аминодикарбоновых кислот, их применение и лекарственное средство
MX9602442A (es) Un tratamiento con fluoroquinolona a dosis unica elevada.
SG49692A1 (en) Process for the production of a pharmaceutical agent for oral or topical administration in the treatment of leishmaniasis
EP0746313A4 (en) METHOD FOR TREATING SMALL Mouth Ulcers
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
PL322284A1 (en) Derivatives of aminoteralin useful in treating diseases of cardiovascular system
AU4361996A (en) The use of inositoltrisphosphate for the preparing of medicaments
MX9704704A (es) Amidas de acido 4-amino-2-ureido-pirimidin-5-carboxilico, procedimientos para su obtencion, medicamentos que contienen estos compuestos, y su utilizacion.
ES2065855A1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
IL101163A (en) Use of flunarizine in the preparation of medicaments for treating neoplastic diseases
AU1400895A (en) 2,3-diaryl-1-benzopyrans for treating dermatitis
AU4578501A (en) Method for treating congestive heart failure
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
AU1675692A (en) Medicaments containing azacyclodiphosphonic acid derivatives, novel azacyclodiphosphonic acid derivatives and process for producing them
UA22022A (ru) Способ лечения больных с высоким риском развития полиоргаhhой hедостаточности
UA22017A (ru) Способ иhтеhсификации энергетического обмена
UA10754A (ru) Способ терапии артериальных гипертензий разного генеза
UA23363A (ru) Способ лечения воспалительных процессов придатков матки
UA35912A (ru) Способ лечения язвенной болезни желудка и двенадцатиперстной кишки
RU98105539A (ru) Способ лечения псориаза
MX9709163A (es) El uso de un compuesto potenciador de dopamina/reductor de prolactina para preparar composiciones para prevenir la estenosis asociada con intervencion despues de intervenciones invasivas sin derivacion.
UA10234A (ru) Способ лечения сахарного диабета
NZ336321A (en) Use of benzothiophene (raloxifene) for treating breast cancer
UA16000A1 (ru) Способ лечения гипотрофии поросят